Rahway, New Jersey Tuesday, October 28, 2025, 12:00 Hrs [IST] ...
Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS ...
The Pensacola News Journal is working with high schools in Escambia and Santa Rosa County to put their top students in the ...
Novartis AG ( NYSE: NVS) M&A Call October 27, 2025 8:00 AM EDT ...
Objective Interstitial lung disease (ILD) represents the most common and severe organ manifestation observed in patients ...
Background Stillbirth rates remain unacceptably high in low- and middle-income countries (LMICs). Understanding the causes of ...
For the sixth year, we present CRN’s Next-Gen Solution Provider Leaders list, recognizing today’s up-and-coming solution ...
220 Triathlon on MSN
Best aero helmets for triathlon speed in 2025
The Lazer Victor KinetiCore is a triathlon-specific helmet designed to be fast and practical on the bike leg. Its tail is ...
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke ...
Previously, the CCFT measured Scope 1 and 2 emissions, but now the company is also incorporating Scope 3 emissions, as well ...
Sotatercept-csrk is approved for improving exercise capacity and reducing clinical worsening in PAH patients, following FDA ...
The device, which is delivered transapically, represents an option for very sick patients who previously have had none.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback